Glycopeptide

Results: 130



#Item
41Lectures and presentations at conferences[removed]Organisches Kolloquium, Universität Jena 16. Januar[removed]scheduled)

Lectures and presentations at conferences[removed]Organisches Kolloquium, Universität Jena 16. Januar[removed]scheduled)

Add to Reading List

Source URL: userpage.chemie.fu-berlin.de

Language: English - Date: 2012-01-10 07:33:56
42Teicoplanin  Rationale for the EUCAST clinical breakpoints, version[removed]June 2010

Teicoplanin Rationale for the EUCAST clinical breakpoints, version[removed]June 2010

Add to Reading List

Source URL: www.eucast.org

Language: English - Date: 2010-06-17 10:53:01
43MRSA drug dosage calculations found to be inaccurate for children over 10

MRSA drug dosage calculations found to be inaccurate for children over 10

Add to Reading List

Source URL: medicalxpress.com

Language: English - Date: 2015-02-10 12:10:45
44Vancomycin  17 June 2010 Rationale for the EUCAST clinical breakpoints, version 2.1

Vancomycin 17 June 2010 Rationale for the EUCAST clinical breakpoints, version 2.1

Add to Reading List

Source URL: www.eucast.org

Language: English - Date: 2010-06-17 10:53:01
45

PDF Document

Add to Reading List

Source URL: www.evolva.com

Language: English - Date: 2012-09-13 02:28:32
46Microwave Assisted Peptide Synthesis  Sanjukta Ghosh Green Chemistry – 671 December 8, 2011

Microwave Assisted Peptide Synthesis Sanjukta Ghosh Green Chemistry – 671 December 8, 2011

Add to Reading List

Source URL: alpha.chem.umb.edu

Language: English - Date: 2011-12-11 22:28:03
47Prof. Jacques Bille, M.D. CHUV - Lausanne EUCAST Enterococci and

Prof. Jacques Bille, M.D. CHUV - Lausanne EUCAST Enterococci and

Add to Reading List

Source URL: www.swissmicrobiology.ch

Language: English - Date: 2014-07-22 18:03:43
48Theravance and Astellas Announce FDA Approval of VIBATIV™ (telavancin) for the Treatment of Complicated Skin and Skin Structure Infections SOUTH SAN FRANCISCO, CA and DEERFIELD, IL – September 11, 2009 – Theravance

Theravance and Astellas Announce FDA Approval of VIBATIV™ (telavancin) for the Treatment of Complicated Skin and Skin Structure Infections SOUTH SAN FRANCISCO, CA and DEERFIELD, IL – September 11, 2009 – Theravance

Add to Reading List

Source URL: www.astellas.com

Language: English - Date: 2009-09-13 21:20:55
49Astellas and Theravance Announce Submission of Telavancin MAA for the Treatment of Nosocomial Pneumonia and Complicated Skin and Soft Tissue Infections in Europe TOKYO, JAPAN AND SOUTH SAN FRANCISCO, CA/October 28, 2009

Astellas and Theravance Announce Submission of Telavancin MAA for the Treatment of Nosocomial Pneumonia and Complicated Skin and Soft Tissue Infections in Europe TOKYO, JAPAN AND SOUTH SAN FRANCISCO, CA/October 28, 2009

Add to Reading List

Source URL: www.astellas.com

Language: English - Date: 2009-10-28 20:07:57
50Volume 8 Number 15 Published on: 17 April[removed]Current News Group A streptococcal infections: third update on seasonal activity, [removed]Infection Reports Bacteraemia

Volume 8 Number 15 Published on: 17 April[removed]Current News Group A streptococcal infections: third update on seasonal activity, [removed]Infection Reports Bacteraemia

Add to Reading List

Source URL: www.gov.uk

Language: English - Date: 2014-07-03 13:03:16